<DOC>
	<DOCNO>NCT00845871</DOCNO>
	<brief_summary>This single-arm , open-label , multi-center study enroll 60 patient approximately 20 center . All patient meet study criterion currently take , begin resume treatment Deferasirox allow . The study begin one month run-in phase , patient instruct take Deferasirox accord physician 's current prescribing information .</brief_summary>
	<brief_title>Palatability Tolerability Deferasirox Taken With Meals , With Different Liquids Crushed Added Food</brief_title>
	<detailed_description>Following run-in phase , patient enter three month , assessment phase . During assessment phase , patient five general option take Deferasirox include without meal , crush added soft food mixed liquid choice .</detailed_description>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Male female patient thalassemia major , sickle cell disease ( SCD ) , low intermediate 1 ( INT 1 ) risk myelodysplastic syndrome ( MDS ) anemias transfusional hemosiderosis . Patients , start , resume treatment Exjade . Patients &gt; 2 year ( i.e. , 2 year age old ) . Exclusion criterion : Serum creatinine upper limit normal ( ULN ) age . Alanine aminotransferase ( ALT ) &gt; 2.5 time ULN.High risk intermediate2 high risk MDS acute leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Exjade</keyword>
	<keyword>deferasirox</keyword>
	<keyword>palatability</keyword>
	<keyword>tolerability</keyword>
	<keyword>food</keyword>
	<keyword>iron overload</keyword>
	<keyword>Serum Iron overload due transfusion</keyword>
</DOC>